Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
EDETATE CALCIUM DISODIUM vs CHEMET
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Chelates heavy metals (e.g., lead, cadmium) by forming stable complexes with divalent and trivalent cations, which are then excreted in urine.
Chelates heavy metals, particularly lead, mercury, and arsenic, by forming soluble complexes that are excreted renally. Acts as an antidote by binding to toxic metals and reducing their tissue concentrations.
Treatment of acute and chronic lead poisoning (FDA-approved).,Treatment of poisoning by radioactive metals such as plutonium, americium, and curium (off-label).,Treatment of manganese intoxication (off-label).,Treatment of cadmium poisoning (off-label).
Treatment of acute and chronic lead poisoning,Treatment of mercury poisoning,Treatment of arsenic poisoning,Diagnostic chelation challenge test
Edetate calcium disodium is administered intravenously or intramuscularly. For lead poisoning: 1000 mg/m²/day IV continuous infusion or in divided doses every 12 hours; alternatively 50 mg/kg/day IV or IM in divided doses every 8-12 hours. Maximum 3000 mg/day. Duration typically 5 days, repeat after 2 days rest. For other heavy metal toxicity: 50 mg/kg/day IV or IM in divided doses every 8-12 hours for 3-5 days.
10-20 mg/kg orally every 8 hours for 5 days; maximum single dose 1250 mg.
Terminal elimination half-life approximately 1.5-3 hours for the intact chelate; prolonged to 20-40 hours in lead-intoxicated patients due to redistribution of lead from bone.
Terminal elimination half-life: 1.6–3.5 hours (mean 2.1 h) in adults with normal renal function; prolonged in renal impairment (up to 20 h).
Not metabolized; excreted unchanged in urine, primarily via glomerular filtration.
Metabolized in liver to disulfide dimers; undergoes enterohepatic circulation; primarily excreted renally as metabolites and unchanged drug.
Primarily renal (90-100% as chelated lead complex within 24-48 hours); minimal biliary/fecal excretion (<5%).
Renal: 80–90% as unchanged drug and metabolites (primarily as chelated complexes); biliary/fecal: <10%.
Negligible (<5%); primarily binds lead in extracellular fluid.
Approximately 80% bound to plasma proteins, primarily albumin.
0.3-0.5 L/kg (confined mainly to extracellular space; does not penetrate cells or CNS).
0.5–0.8 L/kg, indicating distribution mainly in extracellular fluid; limited intracellular penetration.
IV or IM: 100% (not absorbed orally).
20–40% after oral administration due to first-pass metabolism and limited absorption.
GFR > 50 m L/min: no adjustment. GFR 30-50 m L/min: reduce dose by 50%. GFR 15-29 m L/min: reduce dose by 75%. GFR < 15 m L/min or dialysis: contraindicated or use with extreme caution at 10-20% of normal dose with monitoring.
GFR 50-80 m L/min: same dose every 12 hours. GFR 10-49 m L/min: same dose every 24 hours. GFR <10 m L/min: same dose every 48 hours.
No specific guidelines for Child-Pugh based modifications. Use with caution in severe hepatic impairment due to potential for electrolyte disturbances and nephrotoxicity.
No specific recommendations; caution in severe hepatic impairment (Child-Pugh C) due to potential toxicity.
For lead poisoning: 1000 mg/m²/day IV continuous infusion or in divided doses every 12 hours; or 50 mg/kg/day IV or IM in divided doses every 8-12 hours. Maximum 3000 mg/day. Course: 5 days, may repeat after 2 days rest. For other indications: weight-based dosing similar to adults (50 mg/kg/day).
Children >1 year: 10-20 mg/kg/dose orally every 8 hours for 5 days; maximum 1250 mg/dose.
Start at low end of dosing range (e.g., 30-40 mg/kg/day) due to age-related decreased renal function. Monitor renal function and electrolytes closely. Avoid use in patients with pre-existing renal impairment without dose reduction.
Consider starting at lower end of dosing range (10 mg/kg) due to potential renal impairment; adjust per renal function.
Black box warning for nephrotoxicity, particularly at high doses; may cause fatal renal failure. Avoid in patients with renal disease unless benefits outweigh risks. Monitor renal function closely during therapy.
None
Nephrotoxicity - monitor BUN, creatinine, and urinalysis at baseline and during therapy.,Neurotoxicity - may cause tremors, myoclonus, and seizures, especially with high doses.,Hepatotoxicity - monitor liver function tests.,Arrhythmias - may cause QT prolongation; monitor ECG.,Hypocalcemia - monitor serum calcium levels; may cause tetany.,Use with caution in patients with asthma or allergic history.,Not recommended for prophylaxis of heavy metal poisoning.
May cause nephrotoxicity; monitor renal function,May cause hypersensitivity reactions, including fever, rash, and anaphylaxis,Monitor for neutropenia; obtain CBC before and during therapy,Use caution in patients with hepatic impairment or glucose-6-phosphate dehydrogenase (G6PD) deficiency,May chelate essential minerals (e.g., zinc, copper); monitor levels with prolonged use,Not recommended for routine use in asymptomatic lead poisoning with low blood lead levels
Severe renal disease or anuria.,Acute pancreatitis.,Known hypersensitivity to edetate calcium disodium or any component.,Concurrent use with other nephrotoxic drugs.,Pregnancy (only if clearly needed due to risk to fetus from metal poisoning).
Hypersensitivity to dimercaprol or any component of the formulation,Hepatic failure (except severe heavy metal poisoning),Concurrent use with iron (increases nephrotoxicity); avoid iron therapy within 24 hours,Pregnancy (if not life-saving indication due to risk of teratogenicity),Peanut allergy (formulation contains peanut oil)
No specific food restrictions, but maintain adequate hydration. Avoid alcohol due to potential renal effects.
No specific food interactions reported. However, due to gastrointestinal side effects (nausea, vomiting), it is advisable to maintain small, frequent meals. Avoid alcohol.
FDA Pregnancy Category C. In animal studies, edetate calcium disodium has been shown to be teratogenic (skeletal anomalies) at doses approximately 0.25 times the human dose. There are no adequate and well-controlled studies in pregnant women. The drug should be used during pregnancy only if the potential benefit justifies the potential risk to the fetus. First trimester: Risk cannot be ruled out; potential for teratogenic effects. Second and third trimesters: Potential fetal toxicity from chelation of essential minerals; avoid use unless necessary.
FDA Pregnancy Category C. First trimester: No adequate studies, but animal studies show fetal resorption at maternally toxic doses, risk cannot be excluded. Second and third trimesters: No specific teratogenicity, but may cause anemia in fetus due to maternal chelation of essential metals. Avoid use unless clearly needed.
It is not known whether edetate calcium disodium is excreted in human milk. Because many drugs are excreted in human milk and because of the potential for serious adverse reactions in nursing infants, a decision should be made whether to discontinue nursing or to discontinue the drug, taking into account the importance of the drug to the mother. No M/P ratio has been reported.
No human data on excretion in breast milk. M/P ratio unknown. Caution due to potential for infant exposure and chelation of trace elements; consider benefit-risk. Avoid breastfeeding during therapy and for 2 weeks after last dose.
Physiologic increases in renal blood flow and glomerular filtration rate during pregnancy may increase clearance of edetate calcium disodium. Pharmacokinetic data are lacking, but dose adjustments may not be required as dosing is typically based on lead levels and renal function. However, careful monitoring of lead levels and renal function is essential. The drug is contraindicated in patients with severe renal impairment.
No specific dose adjustments recommended for pregnancy. Increased plasma volume in pregnancy may alter pharmacokinetics, but studies not performed. Use lowest effective dose; monitor therapeutic response and toxicity closely.
Edetate calcium disodium is used for chelation therapy in heavy metal poisoning, particularly lead. Monitor renal function closely due to risk of nephrotoxicity. Administer via slow IV infusion (over 8-12 hours) after dilution to minimize irritation. Contraindicated in anuria or severe renal impairment. Rapid infusion may cause hypocalcemic tetany; ensure adequate hydration to enhance lead excretion. Use with caution in patients with arrhythmias due to potential electrolyte disturbances.
Chelation therapy with dimercaprol (CHEMET) should be initiated within 4 hours of arsenic or mercury exposure for maximal efficacy. Administer only via deep intramuscular injection, never intravenously. Monitor renal function and urine output closely, as dimercaprol can cause nephrotoxicity. Alkalinize urine to p H 7.5-8.5 to decrease renal precipitation of metal-drug complexes. Use with caution in patients with glucose-6-phosphate dehydrogenase deficiency due to risk of hemolysis. Contraindicated in patients with peanut allergy (vehicle is peanut oil).
This medication is used to remove lead from your body.,You will receive this drug as an intravenous infusion over several hours.,Drink plenty of fluids during treatment to help flush out lead.,Report any muscle cramps, numbness, or tingling immediately.,Your kidney function and electrolyte levels will be monitored during treatment.,Avoid taking other medications without consulting your doctor, especially those affecting the kidneys.
This medication is given as a shot into a muscle, usually in the buttock. It may cause pain at the injection site.,You may experience a metallic taste, nausea, vomiting, headache, or burning sensation in the mouth or throat.,Drink plenty of fluids unless otherwise instructed to help flush metals from your body.,Avoid alcohol during treatment and for at least 48 hours after the last dose.,Report any signs of allergic reaction (rash, itching, difficulty breathing) or dark urine immediately.
No interactions on record
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about EDETATE CALCIUM DISODIUM vs CHEMET, answered by our medical review team.
EDETATE CALCIUM DISODIUM is a Chelating Agent that works by Chelates heavy metals (e.g., lead, cadmium) by forming stable complexes with divalent and trivalent cations, which are then excreted in urine.. CHEMET is a Chelating agent that works by Chelates heavy metals, particularly lead, mercury, and arsenic, by forming soluble complexes that are excreted renally. Acts as an antidote by binding to toxic metals and reducing their tissue concentrations.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between EDETATE CALCIUM DISODIUM and CHEMET depend on the specific clinical indication. These are agents from distinct pharmacological classes and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of EDETATE CALCIUM DISODIUM is: Edetate calcium disodium is administered intravenously or intramuscularly. For lead poisoning: 1000 mg/m²/day IV continuous infusion or in divided doses every 12 hours; alternatively 50 mg/kg/day IV or IM in divided doses every 8-12 hours. Maximum 3000 mg/day. Duration typically 5 days, repeat after 2 days rest. For other heavy metal toxicity: 50 mg/kg/day IV or IM in divided doses every 8-12 hours for 3-5 days.. The standard adult dose of CHEMET is: 10-20 mg/kg orally every 8 hours for 5 days; maximum single dose 1250 mg.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between EDETATE CALCIUM DISODIUM and CHEMET in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. EDETATE CALCIUM DISODIUM is classified as Category C. FDA Pregnancy Category C. In animal studies, edetate calcium disodium has been shown to be teratogenic (skeletal anomalies) at doses approximately 0.25 times the human dose. There . CHEMET is classified as Category C. FDA Pregnancy Category C. First trimester: No adequate studies, but animal studies show fetal resorption at maternally toxic doses, risk cannot be excluded. Second and third trimes. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.